$102.97 +2.24 (%) Alnylam Pharmaceuticals Inc - NASDAQ

Nov. 28, 2014 | 10:50 AM

Partner Headlines

  1. Alnylam jumps on trial results

    IBD | Oct. 13, 2014 | 18:46PM EST
  2. U.S. Stocks Fluctuate; Shutterfly Shares Decline On Aborted Merger Talks

    Benzinga | Oct. 13, 2014 | 15:18PM EST
  3. Alnylam Drug Scores Against Rare Nerve Disease

    IBD | Oct. 13, 2014 | 13:59PM EST
  4. Midday Gainers From October 13 - Doral Financial, Nanosphere, Ibio, Atlas Energy

    Benzinga | Oct. 13, 2014 | 13:55PM EST
  5. Lithia Motors Dips On Lowered Earnings Forecast; CSX Shares Gain

    Benzinga | Oct. 13, 2014 | 12:30PM EST
  6. Markets Down; Targa To Acquire Atlas Pipeline, Atlas Energy

    Benzinga | Oct. 13, 2014 | 11:05AM EST
  7. Benzinga's Volume Movers

    Benzinga | Oct. 13, 2014 | 10:12AM EST
  8. Morning Market Movers

    Benzinga | Oct. 13, 2014 | 09:39AM EST
  9. Alnylam Broadens Pipeline With ALN-AGT, A Subcutaneously Administered RNAi Therapeutic Targeting Angiotensinogen For The Treatment Of Hypertensive Disorders Of Pregnancy, Including Preeclampsia

    Benzinga | Sep. 12, 2014 | 08:02AM EST
  10. The Biotech Stock With The Biggest Head Of Steam

    Benzinga | Aug. 4, 2014 | 14:35PM EST
  11. Biogen Hemophilia Drugs Launch Into The Unknown

    IBD | Jun. 30, 2014 | 17:00PM EST
  12. Events Scheduled for Week of Jun 23rd to Jun 27th, 2014

    Benzinga | Jun. 23, 2014 | 18:25PM EST
  13. Alnylam Pharma

    IBD | May. 12, 2014 | 18:42PM EST
  14. Alnylam Presents Pre-Clinical Data on RNAi Therapeutics at ISA

    Benzinga | Apr. 29, 2014 | 08:02AM EST
  15. UPDATE: Alnylam, Collaborators to Offer New Clinical Data for Patisiran

    Benzinga | Apr. 28, 2014 | 08:02AM EST
  16. UPDATE: Alnylam Receives Positive Opinion for Orphan Drug Designation in EU for ALN-TTRsc

    Benzinga | Apr. 2, 2014 | 08:05AM EST
  17. Alnylam Initiates Phase 1 Clinical Trial with ALN-AT3, a Subcutaneously Administered RNAi Therapeutic Targeting Antithrombin (AT) in Development for the Treatment of Hemophilia and Rare Bleeding Disorders (RBD)

    Benzinga | Jan. 22, 2014 | 08:03AM EST
  18. UPDATE: Morgan Stanley Downgrades Alnylam Pharmaceuticals, Sees Robust Drug Prospects

    Benzinga | Jan. 14, 2014 | 10:53AM EST
  19. Benzinga's M&A Chatter for Monday January 13, 2014

    Benzinga | Jan. 13, 2014 | 18:05PM EST
  20. Market Wrap For January 13: Markets Showing Weakness Ahead Of Major Earning Releases

    Benzinga | Jan. 13, 2014 | 16:52PM EST
  21. Mid-Afternoon Market Update: Markets Dip Despite Large Amount of M&A

    Benzinga | Jan. 13, 2014 | 16:14PM EST
  22. Mid-Day Market Update: SodaStream Drops After Weak Outlook; Beam Shares Spike Higher

    Benzinga | Jan. 13, 2014 | 12:52PM EST
  23. Mid-Morning Market Update: Markets Open Lower; Lululemon Lowers Q4 Outlook

    Benzinga | Jan. 13, 2014 | 10:39AM EST
  24. UPDATE: JMP Securities Reiterates Market Perform on Alnylam Pharmaceuticals on Therapeutic Candidates

    Benzinga | Jan. 13, 2014 | 10:32AM EST
  25. Morning Market Movers

    Benzinga | Jan. 13, 2014 | 09:54AM EST
  26. Stocks Futures Mildly Lower; Lululemon, Ascena Pare Guidance

    IBD | Jan. 13, 2014 | 09:00AM EST
  27. Benzinga's Top #PreMarket Gainers

    Benzinga | Jan. 13, 2014 | 08:21AM EST
  28. US Stock Futures Fall Ahead Of Federal Budget

    Benzinga | Jan. 13, 2014 | 06:41AM EST
  29. Genzyme, Alnylam Expand Collaboration on Rare Genetic Diseases

    Benzinga | Jan. 13, 2014 | 05:54AM EST
  30. Alnylam Acquires Sirna Therapeutics from Merck for $175M Upfront Payment in Cash, Stock

    Benzinga | Jan. 13, 2014 | 05:53AM EST
  31. Tekmira Receives $5M Milestone Payment from Alnylam

    Benzinga | Dec. 16, 2013 | 20:02PM EST
  32. Alnylam Presents New Pre-clinical Data on ALN-AT3 for Treatment of Hemophilia and RBD at ASH

    Benzinga | Dec. 9, 2013 | 20:59PM EST
  33. Alnylam Earns $7M Milestone Payment from Partner Genzyme for Phase II Success with Patisiran

    Benzinga | Nov. 25, 2013 | 07:02AM EST
  34. Alnylam Presents New Pre-clinical Data on RNAi Therapeutics at American Heart Association Meeting

    Benzinga | Nov. 17, 2013 | 16:54PM EST
  35. Alnylam Announces Positive Phase II Data for Patisiranfor for Treatment of TTR-Mediated Amyloidosis, Initiates Phase III Trial

    Benzinga | Nov. 10, 2013 | 09:26AM EST
  36. Alnylam Presents New Pre-clinical Data on ALN-AAT

    Benzinga | Nov. 2, 2013 | 16:12PM EST
  37. The Medicines Company, Alnylam Announce Advance Development Candidate for Treatment of Hypercholesterolemia

    Benzinga | Oct. 9, 2013 | 06:10AM EST
  38. Alnylam Pharma Announces Advancement of Development Candidate for ALN-AS1

    Benzinga | Oct. 8, 2013 | 08:02AM EST
  39. Pharmaceutical Industry Expected To Collect Billions From Obamacare

    Benzinga | Oct. 2, 2013 | 12:51PM EST
  40. Alnylam Closes Enrollment of Phase II Clinical Trial and Initiates Study with ALN-TTR02

    Benzinga | Sep. 30, 2013 | 08:07AM EST
  41. Alnylam Announces Positive Interim Results from Phase I Clinical Trial of ALN-TTRsc

    Benzinga | Sep. 23, 2013 | 07:12AM EST
  42. Alnylam Confirms Added Orphan Drug Status for ALN-AT3

    Benzinga | Aug. 20, 2013 | 08:02AM EST
  43. Alnylam Confirms Orphan Drug Status for ALN-AT3, RNAI for Hemophilia Treatment

    Benzinga | Aug. 14, 2013 | 08:04AM EST
  44. Jefferies Reiterates Buy Rating, $34 PT on Partnership with Alnylam Pharmaceuticals

    Benzinga | Feb. 4, 2013 | 06:17AM EST
  45. A Peek Into The Market Before The Trading Starts

    Benzinga | Feb. 4, 2013 | 00:10AM EST
  46. The Medicines Company, Alnylam Announce Global Alliance

    Benzinga | Feb. 3, 2013 | 23:21PM EST
  47. Alnylam Pharma Offer Results from Phase I Trial, Extension Study with ALN-VSP

    Benzinga | Jan. 30, 2013 | 01:03AM EST
  48. UPDATE: Piper Jaffray Reiterates Overweight Rating, Raises PT on Alnylam Pharmaceuticals

    Benzinga | Jan. 28, 2013 | 06:46AM EST
  49. Alnylam Pharma Announces Exercise of Underwriter's Over-Allotment Option in Offering

    Benzinga | Jan. 16, 2013 | 09:58AM EST
  50. Alnylam Pharmaceuticals Prices 8M Share Offering at $20.13/Share

    Benzinga | Jan. 15, 2013 | 23:33PM EST
Trading Center